This was the stock's second consecutive day of gains.

Morgan Stanley analyst Tejas Savant lowered the firm’s price target on Charles River (CRL) to $184 from $220 and keeps an Equal Weight rating ...

Charles River Laboratories Financial Overview And Stock Metrics ...

Request To Download Free Sample of This Strategic Report @ Driving Forces Behind the Growth: The robust growth of the Asia Pacific pharmaceutical analytical testing outsourcing market is propelled by ...

North America bioprocess technology market is projected to grow by 13.3% annually in the forecast period and reach $29.68 billion by 2033. The growth is driven an increasing prevalence of chronic ...

Charles River is shuttering its pathology facility in Durham, North Carolina, after determining the site “is not a strategic ...

Shares of Charles River Laboratories International Inc. CRL shed 1.91% to $161.62 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX ...

Charles River Laboratories is permanently closing its pathology facility in Durham, NC, after determining it is no longer “a ...

Members of Congress and animal rights advocates believe the Department of Government Efficiency could end animal testing ...

Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.

In a report released on February 1, Casey Woodring from J.P. Morgan maintained a Hold rating on Charles River Labs (CRL – Research Report), ...

Read here for an analysis of Charles River's (CRL) strong financial performance with high ROE and decreasing liabilities, indicating future capital deployment.